Grapple Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 15-06-2024
- Paid Up Capital ₹ 0.40 M
as on 15-06-2024
- Company Age 13 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 9.90 M
as on 15-06-2024
- Satisfied Charges ₹ 2.40 M
as on 15-06-2024
- Revenue -22.82%
(FY 2023)
- Profit -16.21%
(FY 2023)
- Ebitda -18.65%
(FY 2023)
- Net Worth 12.56%
(FY 2023)
- Total Assets 3.92%
(FY 2023)
About Grapple Lifesciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.40 M.
The company currently has active open charges totaling ₹9.90 M. The company has closed loans amounting to ₹2.40 M, as per Ministry of Corporate Affairs (MCA) records.
Ajay and Satwant Singh serve as directors at the Company.
- CIN/LLPIN
U24230CH2011PTC033379
- Company No.
033379
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Nov 2011
- Date of AGM
27 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Manimajra, Chandigarh, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Grapple Lifesciences Private Limited offer?
Grapple Lifesciences Private Limited offers a wide range of products and services, including Anti Infective Drugs & Medicines, Antifungal Injection, Tablet & Syrup, Antibacterial Drugs, Pharma & Bioanalytical Services, PCD Pharma Franchise, Pain Relief Drugs & Pharmaceuticals, Anti Inflammatory Drugs, Nutraceuticals & Dietary Supplements, Vitamin Tablets & Capsules, Sexual Wellness Products.
Who are the key members and board of directors at Grapple Lifesciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ajay  | Additional Director | 05-Jan-2024 | Current |
| Satwant Singh | Director | 20-Nov-2012 | Current |
Financial Performance of Grapple Lifesciences.
Grapple Lifesciences Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 22.82% decrease. The company also saw a substantial fall in profitability, with a 16.21% decrease in profit. The company's net worth Soared by an impressive increase of 12.56%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Grapple Lifesciences?
In 2023, Grapple Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 18 Apr 2023 | ₹9.90 M | Open |
Idbi Bank Limited Creation Date: 11 Dec 2017 | ₹1.00 M | Satisfied |
Icici Bank Limited Creation Date: 19 Nov 2015 | ₹0.70 M | Satisfied |
How Many Employees Work at Grapple Lifesciences?
Unlock and access historical data on people associated with Grapple Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Grapple Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Grapple Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
